Changes in left ventricular mass during treatment with minoxidil and cilazapril in hypertensive patients with left ventricular hypertrophy

Journal of Human Hypertension

Volumn 11, Issue 3, 1997, Pages 149-156

  Pogatsa Murray G ^a   Varga, L ^a   Varga, A ^a   Abraham Gy ^a   Nagy, I ^a   Forster, T ^a   Csanady M ^a   Sonkodi, S ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Angiotensin converting enzyme inhibitor; Cilazapril; Left ventricular hypertrophy; Minoxidil; Vasodilator

Indexed keywords

ANTIHYPERTENSIVE AGENT; BOPINDOLOL; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GUANFACINE; MINOXIDIL; POTASSIUM CHANNEL STIMULATING AGENT;

ADULT; ARTERIAL PRESSURE; ARTICLE; CLINICAL ARTICLE; ECHOCARDIOGRAPHY; ESSENTIAL HYPERTENSION; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; MALE;

EID: 0030960390     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1000410     Document Type: Article

References (51)

1. Levy D et al. Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors: the Framingham Study. Ann Intern Med 1988; 108: 7-13.
2. Kannel WB. Left ventricular hypertrophy as a risk factor: the Framingham experience. J Hypertens 1991; 9 (Suppl 2): S3-S9.
3. Levy D et al. Determinants of sensitivity and specificity of ECG criteria for left ventricular hypertrophy. Circulation 1990; 81: 815-820.
4. Koren MJ et al. Relation of left ventricular mass and geometry to morbidity and mortality in men and women with essential hypertension. Ann Intern Med 1991; 114: 345-352.
5. Levy D et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-1566.
6. Schmieder RE, Martus P, Klingheil A, Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 1996; 275: 1507-1513.
7. Liebson PR. Clinical studies of drug reversal of hypertensive left ventricular hypertrophy. Am J Hypertens 1990; 3: 512-517.
8. Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens 1992; 7: 95-110.
9. Koren MJ, Ulin RJ, Laragh JH, Devereux RB. Reduction in left ventricular mass during treatment of essential hypertension is associated with improved prognosis. Am J Hypertens 1991; 4: 1A.
10. Levy D et al. Prognostic: implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994; 90: 1786-1793.
11. Cruickshank JM, Lewis J, Moore V, Dodd C. Reversibility of LVH by differing types of antihypertensive therapy. J Hum Hvpertens 1992; 6: 85-90.
12. Knorr X, Garthoff B, Kazda S, Stasch J. Effects of different antihypertensive drug classes on survival in animal models. J Cardiovasc Pharmacol 1991; 17 (Suppl 2): S94-S100.
13. Tsoporis J, Fields N, Lee RM, Leenen FH. Effects of the arterial vasodilator minoxidil on cardiovascular structure and sympathetic activity in spontaneously hypertensive rats. J Hypertens 1993; 11: 1337-1345.
14. Ruzicka M, Yuan B, Leenan FH. Effects of enalapril versus losartan of regression on volume overload-induced cardiac hypertrophy in rats. Circulation 1994; 90: 484-491.
15. Moravec CS et al. Structural and functional consequences of minoxidil-induced cardiac hypertrophy. J Pharmacol Exp Ther 1994; 269: 290-296.
16. Andreucci VE et al. Long-term follow-up of minoxidil therapy in refractory hypertension. A prospective trial in patients with various degrees of renal insufficiency. Clin Nephrol 1983; 19: 55-60.
17. Toto RD, Mitchell HC, Pettinger WA. Treatment of hypertension in nondiabetic renal disease. Curr Opin Nephrol Hypertens 1994; 3: 279-285.
18. Wilburn RL, Blaufuss A, Bennett CM. Long-term treatment of severe hypertension with minoxidil, propranolol and furosemide. Circulation 1975; 52: 706-713.
19. Mitchell HC, Pettinger WA. Long-term treatment of refractory hypertensive patients with minoxidil. JAMA 1978; 239: 2131-2138.
20. Chrysant SG, Chrysant C, Sadeghi M, Berlin L. Cardiac changes from beta-blocker, diuretic and minoxidil combination in hypertension. Cardiology 1991; 78: 45-52.
21. Julien J et al. Effects of captopril and minoxidil on left ventricular hypertrophy in resistant hypertensive patients: a 6-month double blind comparison. J Am Coll Cardiol 1990; 16: 137-142.
22. Szücs T. Cilazapril. A review. Drugs 1991; 41 (Suppl 1): 18-24.
23. Devereux RB et al. Standardization of M-mode echocardiographic left ventricular anatomic measurements. J Am Coll Cardiol 1984; 4: 1222-1230.
24. Devereux RB et al. Echocardiographic detection of pressure-overload left ventricular hypertrophy: effect of criteria and patient population. J Clin Hypertens 1987; 3: 66-78.
25. Fragerborg B et al. Withdrawal of antihypertensive drug treatment: time course for redevelopment of hypertension and effects upon left ventricular mass. J Hypertens 1992; 10: 587-593.
26. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072-1083.
27. Devereux RD, Reicheck N. Echocardiographic determination of left ventricular mass in man: anatomic validation of the method. Circulation 1977; 55: 613-618.
28. Devereux RB, Pickering TG, Cody RJ, Laragh JH. Relation of renin-angiotensin system activity to left ventricular hypertrophy and function in experimental and human hypertension. J Clin Hypertens 1987; 3: 87-103.
29. Teichholz LE, Kreulen T, Herman MV, Gorlin R. Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence or absence of asynergy. Am J Cardiol 1976; 37: 7-11.
30. Devereux RB, Dahlöf B. Criteria for an informative trial of left ventricular hypertrophy regression, J Hum Hypertens 1994; 8: 735-739.
31. Franciosa JA. Cohn JN. Effects of minoxidil on homodynamics in patients with congestive heart failure. Circulation 1981; 63: 652-657.
32. Franciosa JA, Jordan RA, Wilen MM, Ledy CL. Minoxidil in patients with chronic left ventricular failure: contrasting hemodynamic effects in a controlled trial. Circulation 1984; 70: 63-68.
33. Nathan M, Rubin SA, Siemienczuk D, Swan HJ. Effects of acute and chronic minoxidil administration on rest and exercise hemodynamics and clinical status in patients with severe, chronic heart failure. Am J Cardiol 1982; 50: 900-966.
34. Sanchez RA et al. Long-term evaluation of cilazapril in severe hypertension. Assessment of left ventricular and renal function. Am J Med 1989; 87 (6B): 56S-60S.
35. Haberbosch W et al. Improvement of diastolic filling in hypertensive patients treated with cilazapril. J Cardiovasc Pharmacol 1991; 17 (Suppl 2): S159-S162.
36. De Simone R et al. Effect of cilazapril therapy on diastolic filling and left ventricular hypertrophy in patients with arterial hypertension. Minerva Cardioangiol 1993; 41: 205-209.
37. Abi-Samra F, Fouad FM, Tarazi RC. Determinants of left ventricular hypertrophy and function in hypertensive patients. An echocardiographic study. Am J Med 1983; 75: 26-33.
38. Devereux RB et al. Left ventricular hypertrophy in patients with hypertension: importance of blood pressure response to regularly recurring stress. Circulation 1983; 68: 470-476.
39. Hammond IW, Devereux RB, Alderman MH, Laragh JH. Relation of blood pressure and body build to left ventricular mass in normotensive and hypertensive employed adults. J Am Coll Cardiol 1988; 12: 996-1004.
40. Lauer MS, Anderson KM, Levy D. Influence of contemporary versus 30-year blood pressure levels on left ventricular mass and geometry: the Framingham Heart Study. J Am Coll Cardiol 1991; 18: 1287-1294.
41. Prisant LM, Carr AA. Ambulatory blood pressure monitoring and echocardiographic left ventricular wall thickness and mass. Am J Hypertens 1990; 3: 81-89.
42. Grossman E et al. Left ventricular mass in hypertension: correlation with casual, exercise and ambulatory blood pressure. J Hum Hypertens 1994; 10: 741-746.
43. Frohlich ED. Pathophysiological considerations in left ventricular hypertrophy. J Clin Hypertens 1987; 3: 54-65.
44. Dahlöf B, Hansson L. Regression of left ventricular hypertrophy in previously untreated essential hypertension: different effects of enalapril and hydrochlorothiazide. J Hypertens 1992; 10: 1513-1524.
45. Ruskoaho H. Prevention of cardiac hypertrophy by long-term treatment with isosorbide dinitrate and prazosin but not by minoxidil in spontaneously hypertensive rats. Acta Pharmacol Toxicol (Copenh) 1984; 54: 154-157.
46. Leenen FHH et al. Vasodilators and regression of left ventricular hypertrophy. Hydralazine versus prazosin in hypertensive humans. Am J Med 1987; 82: 969-978.
47. Verdecchia P et al. Adverse prognostic significance of concentric remodeling of the left ventricle in hypertensive patients with normal left ventricular mass. J Am Coll Cardiol 1995; 25: 871-878.
48. Cooke HM, De Besse A. Angiotensin converting enzyme inhibitor-induced renal dysfunction: recommendations for prevention. Int J Clin Pharmacol Ther 1994; 32: 65-70.
49. Tsoporis J, Fields N, Lee RM, Leenen FH. Arterial vasodilation and cardiovascular structural changes in normotensive rats. Am J Phvsiol 1991; 260: H1944-H1952.
50. Dahlöf B. Factors involved in the pathogenesis of hypertensive cardiovascular hypertrophy. A review. Drugs 1988; 35 (Suppl 5): 6-26.
51. Johnston CI. Tissue angiotensin-converting enzyme in cardiac and vascular hypertrophy, repair, and remodeling. Hypertension 1994; 23: 258-268.